Published in Science on November 01, 2013
Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature (2014) 3.50
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity (2014) 2.42
Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature (2015) 1.72
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol (2015) 1.64
Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol (2014) 1.28
Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog (2015) 1.23
Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep (2015) 1.18
Vaccines for the 21st century. EMBO Mol Med (2014) 1.17
Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med (2015) 1.17
Asthma: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc (2014) 1.12
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun (2015) 1.12
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A (2014) 1.06
Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun (2015) 1.02
Pre-fusion structure of a human coronavirus spike protein. Nature (2016) 1.01
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. J Virol (2015) 1.00
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A (2014) 0.99
Novel antigens for RSV vaccines. Curr Opin Immunol (2015) 0.99
A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis (2014) 0.96
Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis (2015) 0.96
Transplanting supersites of HIV-1 vulnerability. PLoS One (2014) 0.96
Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc Natl Acad Sci U S A (2014) 0.95
Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy. Structure (2015) 0.94
Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. J Virol (2015) 0.93
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun (2015) 0.93
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. J Virol (2015) 0.92
Designing vaccines for the twenty-first century society. Front Immunol (2014) 0.92
Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J Clin Invest (2014) 0.92
Immunity to RSV in Early-Life. Front Immunol (2014) 0.92
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol (2015) 0.92
Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol (2015) 0.90
HIV: A stamp on the envelope. Nature (2014) 0.88
Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol (2014) 0.88
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med (2016) 0.87
Strategies to guide the antibody affinity maturation process. Curr Opin Virol (2015) 0.87
Antiviral B cell and T cell immunity in the lungs. Nat Immunol (2015) 0.86
Roles of the putative integrin-binding motif of the human metapneumovirus fusion (f) protein in cell-cell fusion, viral infectivity, and pathogenesis. J Virol (2014) 0.86
A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. J Virol (2014) 0.86
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner. PLoS One (2015) 0.86
Early-life viral infections and the development of asthma: a target for asthma prevention? Curr Opin Allergy Clin Immunol (2014) 0.86
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol (2016) 0.85
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. J Immunol Res (2015) 0.85
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest (2015) 0.85
Immunosilencing a highly immunogenic protein trimerization domain. J Biol Chem (2015) 0.85
Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model. J Virol (2014) 0.85
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. PLoS One (2015) 0.85
Rapid Fine Conformational Epitope Mapping Using Comprehensive Mutagenesis and Deep Sequencing. J Biol Chem (2015) 0.84
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev (2017) 0.83
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses (2015) 0.83
RNA virus reverse genetics and vaccine design. Viruses (2014) 0.82
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. Front Immunol (2014) 0.82
The Bordetella adenylate cyclase repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies. J Biol Chem (2014) 0.82
Determinants of early life immune responses to RSV infection. Curr Opin Virol (2016) 0.81
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. PLoS One (2016) 0.81
Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins. PLoS Pathog (2016) 0.81
HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. Gut (2015) 0.81
Structure and stabilization of the Hendra virus F glycoprotein in its prefusion form. Proc Natl Acad Sci U S A (2015) 0.81
Vaccines against respiratory syncytial virus: The time has finally come. Vaccine (2016) 0.81
Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. ILAR J (2014) 0.80
Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. PLoS One (2015) 0.80
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proc Natl Acad Sci U S A (2016) 0.79
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. J Virol (2016) 0.79
Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. J Virol (2015) 0.79
A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. PLoS One (2016) 0.79
Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest (2015) 0.79
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol (2016) 0.78
Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine. J Virol (2015) 0.78
Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection. Vaccine (2014) 0.78
Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med (2015) 0.78
Stable long-term cultures of self-renewing B cells and their applications. Immunol Rev (2016) 0.78
Parainfluenza virus 5 (PIV5) expressing wild-type or pre-fusion respiratory syncytial virus (RSV) fusion protein protect mice and cotton rats from RSV challenge. J Virol (2017) 0.77
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun (2016) 0.77
Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol (2016) 0.77
New challenges in modern vaccinology. BMC Immunol (2015) 0.77
Protein Crystallography in Vaccine Research and Development. Int J Mol Sci (2015) 0.77
Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol (2014) 0.77
Delivering vaccines to the people who need them most. Philos Trans R Soc Lond B Biol Sci (2015) 0.77
Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A (2016) 0.77
Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc Natl Acad Sci U S A (2016) 0.77
Emerging Vaccine Technologies. Vaccines (Basel) (2015) 0.77
Protein-Protein Interactions of Viroporins in Coronaviruses and Paramyxoviruses: New Targets for Antivirals? Viruses (2015) 0.77
Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathog (2016) 0.77
Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV. J Virol (2016) 0.77
How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert Rev Vaccines (2016) 0.77
Current views on the potential for development of a HIV vaccine. Expert Opin Biol Ther (2017) 0.77
Evolution of B cell analysis and Env trimer redesign. Immunol Rev (2017) 0.76
Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45. Protein Sci (2015) 0.76
Inhibitory Antibodies Targeting Emerging Viruses: Advancements and Mechanisms. Clin Vaccine Immunol (2016) 0.76
Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. J Virol (2015) 0.76
Vaccines. Structural biology triumph offers hope against a childhood killer. Science (2013) 0.76
Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine (2016) 0.76
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS (2017) 0.76
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Clin Vaccine Immunol (2016) 0.76
Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. Viruses (2016) 0.75
Viral diseases: Zeroing in on RSV vaccine design. Nat Rev Drug Discov (2013) 0.75
Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present. PLoS One (2015) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 4.92
The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol (2005) 4.19
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med (2013) 2.31
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science (2011) 2.17
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A (2012) 1.80
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature (2013) 1.73
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A (2013) 1.51
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 1.39
Structural vaccinology starts to deliver. Nat Rev Microbiol (2012) 1.22
Philosophy of science. The coordinates of truth. Science (2009) 1.18
Collagen stabilization at atomic level: crystal structure of designed (GlyProPro)10foldon. Structure (2003) 1.17
N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. PLoS One (2013) 1.09
Fibritin encoded by bacteriophage T4 gene wac has a parallel triple-stranded alpha-helical coiled-coil structure. J Mol Biol (1994) 1.06
Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins. Protein Eng (1998) 1.04
Characterization of the carboxypeptidase involved in the proteolytic cleavage of the influenza haemagglutinin. J Gen Virol (1983) 1.01
Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med (2013) 1.01
Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr Opin Microbiol (2006) 0.99
The complete genome of an individual by massively parallel DNA sequencing. Nature (2008) 52.81
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
A catalog of reference genomes from the human microbiome. Science (2010) 8.10
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol (2011) 5.05
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol (2008) 4.94
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature (2006) 4.80
A SNP discovery method to assess variant allele probability from next-generation resequencing data. Genome Res (2009) 4.78
Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol (2009) 4.73
Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol (2008) 4.69
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys (2010) 4.14
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency. Proc Natl Acad Sci U S A (2009) 3.82
A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. Acta Crystallogr D Biol Crystallogr (2005) 3.75
MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature (2009) 3.66
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol (2010) 3.40
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity (2012) 3.15
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 3.04
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med (2008) 3.03
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell (2003) 3.03
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics (2009) 3.00
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol (2002) 2.91
Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol (2013) 2.82
Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology (2015) 2.81
Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (2002) 2.81
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure (2008) 2.74